(Yicai  Global) March 18 -- Kehua Bio-Engineering's share price jumped by the  daily limit today after the Chinese pharmaceutical firm said that its  Covid-19 testing kits now have the credentials to be sold in the  European Union and exported to countries that have trade treaties with  the EU.

Kehua's stock price [SHE:002022] climbed by 10 percent to CNY15.51 (USD2.21) this morning, the highest in two weeks.

The  four types of diagnostics tools developed by the company, including  nucleic acid and antibody tests, have received the European Certificates  of Free Sale, the Shanghai-based firm said in a filing to the Shenzhen  Stock Exchange yesterday.

Editor: Emmi Laine